α1-Antitrypsin is synthesised in the liver and released into the circulation, where it is the most abundant circulating protease inhibitor. Most individuals carry two copies of the normal M allele. One in 25 Caucasians of North European descent, however, carry the Z allele that results from the substitution of a lysine for glutamic acid at position 342 in the polypeptide chain. Over the past 20 years we have used a range of techniques to show that the Z allele causes α1-antitrypsin to misfold and form ordered polymers that are retained within the endoplasmic reticulum of hepatocytes [1-4]. Individuals who are homozygous for the Z allele develop cirrhosis as a consequence of α1-antitrypsin entrapment-induced hepatocyte death. The lack of circulating α1-antitrypsin predisposes to early-onset emphysema.

We have focused our efforts on a cure for α1-antitrypsin deficiency by designing peptides and small molecules that can block polymerisation in vitro [5]. An alternative approach to this and other related inherited metabolic disorders of the liver is to use whole cells for therapy. Animal models have demonstrated that wild-type hepatocytes have a selective advantage when transplanted into the liver of a mouse with a genetic abnormality [6]. However, the translation of such studies into the human context has been disappointing [7]. This disappointment is due to the scarce availability of large numbers of high-quality hepatocytes. An additional problem, common to whole-organ transplantation, is the continued requirement for lifelong harmful immunosuppression. Seminal work by Takahashi and Yamanaka raised the exciting possibility that induced pluripotent stem cells (iPSCs) could be used to generate large quantities of high-quality cells for autologous transplantation [8].

We explored the prospect of iPSC-based cell therapy by deriving fibroblasts from skin biopsies of individuals who are homozygous for Z-allele α1-antitrypsin deficiency (PiZ). These cells were reprogrammed with retroviral constructs that overexpressed key pluripotency-associated transcription factors to produce patient-specific iPSCs. The stem cells were then differentiated using a novel in-house protocol to produce hepatocytes that recapitulated many of the features of the clinical phenotype [9]. Specifically the hepatocyte-like cells from PiZ homozygotes formed polymers that were retained within the endoplasmic reticulum [9]. This potentially limitless supply of cells provided us with a useful new model since, unlike previous cell models, the mutant α1-antitrypsin is under the control of the endogenous promoter.

The use of iPSCs within the context of treating individuals with PiZ would require correction of the underlying genetic abnormality in a manner fully compatible with clinical applications. The genetic defect responsible for PiZ (Glu342Lys) was therefore targeted using a combination of engineered zinc finger nucleases and a piggyBac donor vector in patient-specific iPSCs [10]. Through this approach we successfully demonstrated for the first time an efficient gene-editing technique capable of restoring normal structure, function and secretion of α1-antitrypsin in subsequently derived liver cells. This genetic correction did not leave residual exogenous sequences in the targeted iPSC genome. The drawback of this approach is that retroviral reprogramming vectors remain within the genome. We therefore derived human iPSC lines using a nonintegrating RNA (Sendai) virus and produced corrected hepatocytes with stable karyotypes in almost completely chemically defined culture conditions. Given the concern surrounding the safety of stem cell products, however, more effort was required to understand the genetic stability of human iPSC lines. Lines were characterised not only at the

*Correspondence: dal16@cam.ac.uk
Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 2XY, UK
Full list of author information is available at the end of the article

© 2012 BioMed Central Ltd

http://stemcellres.com/content/3/1/4

Stem cell research & therapy

Stem cell-based therapy for α1-antitrypsin deficiency
S Tamir Rashid1,2 and David A Lomas*
chromosome number level (by G-banding), but also for copy number variation (using array-based comparative genomic hybridisation) and single base pair resolution (using whole exome sequencing). A large proportion of Sendai virus-programmed human iPSCs carried the correct numbers of chromosomes but had significant copy number variation detected by array-based comparative genomic hybridisation. Lines genetically stable by array-based comparative genomic hybridisation could be identified and these were subjected to whole exome sequencing. This analysis revealed that whilst the gene correction technique did not perturb the genome, the initial derivation of nonretroviral human iPSC lines induced 29 exonic point mutations.

The biological relevance of the point mutations in iPSC-derived hepatocytes is unclear as none of the new mutations occurred in genes known to predispose to cancer. Moreover, to the best of our knowledge such an in-depth analysis of human cell lines has not previously been performed. We therefore investigated the behaviour of the cells in vivo by injecting genetically corrected iPSC-derived liver cells into a mouse model of liver injury. This assay confirmed the functional capacity of our cells and importantly demonstrated that the point mutations did not cause catastrophic carcinogenic sequelae since none of the mice developed tumours. In total, our results provided proof of principle for the potential of combining human iPSCs with gene therapy techniques to generate cells for autologous cell-based treatment of individuals with α1-antitrypsin deficiency.

Several challenges remain before this technology can be applied within the context of a clinical trial. First, the cell type produced in vitro remains of a foetal nature in terms of its functionality, and great efforts must now be made to improve protocols of differentiation to realise the final step of maturation in order to achieve truly adult-like cells. The final step of maturation, however, may perhaps only be achieved within an extracellular niche of the human liver. If this was to be the case then, as long as the iPSC-derived hepatocytes can be shown to be safe, a move towards the clinic seems rational. Defining safety will require considerable discussion amongst scientists and clinicians alike and will need more comprehensive animal data than we had the time to perform in our study. In the interim, our work opens the possibility that, with the correct level of screening, iPSC-derived products may soon realise their much anticipated use for the treatment of human disorders.

**Abbreviations**

iPSC, induced pluripotent stem cell; PiZ, Z-allele α1-antitrypsin deficiency.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgements**

The present work was funded by the Wellcome Trust, MRC, and the Cambridge Hospitals National Institute for Health Research Biomedical Research Center. STR is a Wellcome Trust Clinical Training Fellow.

**Author details**

1. Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, UK.
2. Laboratory for Regenerative Medicine, University of Cambridge, Cambridge CB2 0SZ, UK.

Published: 9 February 2011

**References**

1. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 1992, 357:605-607.
2. Miranda E, Pérez J, Ekeowa UI, Hozic N, Kalsheker N, Gooptu B, Portmann B, Belorgey D, Hill M, Chambers S, Teckman J, Alexander GJ, Marciniak SJ, Lomas DA. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with α1-antitrypsin deficiency. Hepatology 2010, 52:1078-1088.
3. Ekeowa UI, Freeke J, Miranda E, Gooptu B, Bush MF, Pérez J, Teckman J, Robinson CV, Lomas DA. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci U S A 2010, 107:17146-17151.
4. Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem 2009, 78:147-176.
5. Mallya M, Phillips RL, Saldanha SA, Gooptu B, Brown SC, Termine DJ, Shrivani AM, Wu Y, Sifers RN, Abagyan R, Lomas DA. Small molecules block the polymerization of Z α1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 2007, 50:5357-5363.
6. Ding J, Yannam GR, Roy-Chowdhury N, Hidvegi T, Basma H, Rennard SI, Wong RJ, Avsar Y, Guha C, Perlmutter DH, Fox U, Roy-Chowdhury J. Spontaneous hepatic repopulation in transgenic mice expressing mutant human α1-antitrypsin by wild-type donor hepatocytes. J Clin Invest 2011, 121:1930-1934.
7. Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006, 82:441-449.
8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:633-646.
9. Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas DA, Vallier L. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010, 120:3127-3136.
10. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, Miranda E, Ordóñez A, Hannan NR, Rouhani FJ, Darche S, Alexander G, Marciniak SJ, Fusaki N, Hasegawa M, Holmes MC, Di Santo JP, Lomas DA, Bradley A, Vallier L. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011, 478:391-394.

**Cite this article as:** Rashid ST, Lomas DA. Stem cell-based therapy for α1-antitrypsin deficiency. Stem Cell Research & Therapy 2012, 3:4.

doi:10.1186/scrt95